FDA Drug Safety Podcast: FDA revises description of mental health side effects of stop-smoking medicines Chantix and Zyban to reflect clinical trial findings
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - January 27, 2021 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA revises description of mental health side effects of stop-smoking medicines Chantix and Zyban to reflect clinical trial findings
On December 16, 2016, the FDA announced that based on our review of a large clinical trial that we required the drug companies to conduct, we have determined the risk of serious side effects on mood, behavior, or thinking with the stop-smoking medicines Chantix (active ingredient varenicline) and Zyban (active ingredient bupropion) is lower than previously suspected. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 9, 2017 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
New Weight-Loss Drugs: When to Prescribe?
Dr. Steven Smith reviews 2 weight-loss drugs in the pipeline, liraglutide and naltrexone/bupropion, and discusses how to prescribe such drugs and appropriate patients to receive them. (Source: Medscape Diabetes & Endocrinology Podcast)
Source: Medscape Diabetes & Endocrinology Podcast - June 20, 2014 Category: Endocrinology Authors: Medscape Source Type: podcasts
Smoking Cessation: Varenicline Alone or With Bupropion?
Does bupropion boost the smoking cessation benefits of varenicline? (Source: Medscape Pulmonary Medicine Podcast)
Source: Medscape Pulmonary Medicine Podcast - March 7, 2014 Category: Respiratory Medicine Authors: Medscape Source Type: podcasts
JAMA: 2006-07-05, Vol. 296, No. 1, Author in the Room Audio Interview
Interview with David Gonzales, PhD, and Stephen Rennard, MD, authors of Helping Patients Stop Smoking: Varenicline vs Bupropion, published in the July 5 issue of JAMA, the Journal of the American Medical Association. Summary Points: 1. There is a new and novel pharmaceutical approach to treating nicotine addiction that helps smokers quit by specifically targeting nicotine receptors. 2. Efficacy for varenicline was three to four times that of placebo and twice that of bupropion at the end of 12 weeks of treatment, but abstinence rates in all groups declined after drug treatment ended. 3. The launch of a new smoking cessatio...
Source: JAMA Author in the Room - September 22, 2006 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
